PMID- 19758316
OWN - NLM
STAT- MEDLINE
DCOM- 20100629
LR  - 20151119
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Linking)
VI  - 19
IP  - 3
DP  - 2010 Mar
TI  - CC chemokines as potential immunologic markers correlated with clinical 
      improvement of atopic dermatitis patients by immunotherapy.
PG  - 246-51
LID - 10.1111/j.1600-0625.2009.00971.x [doi]
AB  - Although immunotherapy is not accepted as a curative treatment for atopic 
      dermatitis (AD), most studies have shown positive effects of immunotherapy on AD 
      patients. The serum levels of CC chemokine ligand 17 (CCL17), CCL22 and CCL18 
      have been reported to be highly correlated with disease severity, which suggests 
      important roles for CC chemokines in the pathogenesis of AD. OBJECTIVE: The 
      purpose of this study was to investigate the changes in clinical and immunologic 
      markers before and after immunotherapy and to find which CC chemokines correlate 
      with clinical improvement after immunotherapy with house dust mite (HDM) 
      allergens in AD patients. METHODS AND RESULTS: A total of 20 AD patients who were 
      sensitized to HDM allergens through a skin-prick test and Pharmacia CAP system 
      were treated with subcutaneous immunotherapy using HDM allergens (treatment 
      duration 12-60 months). Eczema area and severity index scores in 20 patients with 
      AD decreased significantly after immunotherapy (P < 0.001). Serum total 
      immunoglobulin E (IgE) and Dermatophagoides pteronyssinus-specific IgE levels 
      tended to decrease after treatment although this was not statistically 
      significant, and the D. farinae-specific IgE level showed no change. Serum CCL17, 
      CCL22 and CCL18 levels decreased significantly from baseline after treatment (P = 
      0.043, 0.017 and <0.001, respectively). The percentage reductions in serum CCL17 
      and CCL22 level were significantly correlated with reductions in disease severity 
      (P = 0.007, R(2) = 0.301 and P = 0.037, R(2) = 0.177, respectively). CONCLUSION: 
      We suggest that CCL17 and CCL22 are good immunological marker candidates that can 
      be used to assess clinical improvement after immunotherapy in AD patients.
FAU - Kwon, Yeon Sook
AU  - Kwon YS
AD  - Department of Dermatology and Cutaneous Biology Research Institute, Yonsei 
      University College of Medicine, Seoul, Korea.
FAU - Oh, Sang Ho
AU  - Oh SH
FAU - Wu, Wen Hao
AU  - Wu WH
FAU - Bae, Byung Gi
AU  - Bae BG
FAU - Lee, Hee Jung
AU  - Lee HJ
FAU - Lee, Min-Geol
AU  - Lee MG
FAU - Lee, Kwang Hoon
AU  - Lee KH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090916
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Biomarkers)
RN  - 0 (CCL17 protein, human)
RN  - 0 (CCL18 protein, human)
RN  - 0 (CCL22 protein, human)
RN  - 0 (Chemokine CCL17)
RN  - 0 (Chemokine CCL22)
RN  - 0 (Chemokines, CC)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Antigens, Dermatophagoides/administration & dosage
MH  - Biomarkers/blood
MH  - Chemokine CCL17/blood
MH  - Chemokine CCL22/blood
MH  - Chemokines, CC/*blood
MH  - Child
MH  - Dermatitis, Atopic/*immunology/pathology/*therapy
MH  - Dermatophagoides farinae/immunology
MH  - Dermatophagoides pteronyssinus/immunology
MH  - Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Young Adult
EDAT- 2009/09/18 06:00
MHDA- 2010/06/30 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2010/06/30 06:00 [medline]
AID - EXD971 [pii]
AID - 10.1111/j.1600-0625.2009.00971.x [doi]
PST - ppublish
SO  - Exp Dermatol. 2010 Mar;19(3):246-51. doi: 10.1111/j.1600-0625.2009.00971.x. Epub 
      2009 Sep 16.